Tumor-selective CTLA-4 antagonists
US11279752B2 · kind B2 · utility
0Cited by
26References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 3, 2019 |
| Grant date | Mar 22, 2022 |
| Priority date | — |
| Expiry date | Sep 3, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/50
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Provided herein are recombinant masking proteins and recombinant ligand proteins useful in treating cancer, neurodegenerative disease, and cardiovascular disease. The recombinant masking proteins provided herein may, inter alia, be used as non-covalent masks of antagonists of, for example, cellular growth factors (e.g., TNF) or cell surface proteins (e.g., CTLA-4).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.